BioSpace News Archive

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2023 after the market closes on Tuesday, May 9, 2023.

Gracell Biotechnologies Inc. announced that the company has filed its annual report on Form 20-F for the full year ended December 31, 2022 with the U.S. Securities and Exchange Commission on April 25, 2023.

10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced that members of its management team will participate in a fireside chat at the BofA Securities 2023 Healthcare Conference on Wednesday, May 10, at 2:20 p.m. Pacific Time.

Haemonetics Corporation announced that the Company intends to publish fourth quarter and fiscal year 2023 financial results at 6:00 am ET on Thursday, May 11, 2023.

The Board of Directors of PerkinElmer, Inc. declared a regular quarterly dividend of $0.07 per share of common stock.

Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD) today announced that it will issue its financial results press release for the fiscal 2023 third quarter ended March 31, 2023, on Tuesday, May 9, 2023 after the close of the stock market, and host a conference call at the same day at 5:00 p.m. Eastern Time to discuss the results.

Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of the market.

Medtronic plc, the global leader in medical technology, announced that the U.S. Food and Drug Administration lifted the warning letter received at the company’s Diabetes headquarters in Northridge, California, in December 2021.

Illumina, Inc. announced its financial results for the first quarter of fiscal year 2023, which include the consolidated financial results for GRAIL.

Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 39th Annual Strategic Decisions Conference on Wednesday, May 31st, at the New York Hilton Midtown in New York. Joaquin Duato, Chairman of the Board and Chief Executive Officer will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time).